Medicare Advantage Growth Supports CVS Margin Stabilization Thesis

What happened

A new Forbes report indicates Medicare Advantage continues to add members despite insurer exits, now covering 55% of eligible beneficiaries. This top-line growth aligns with CVS's Health Care Benefits segment, which showed improved margins in Q2 2025 after 2024's utilization spike. The company's integrated model and pricing transparency initiatives (TrueCost, CostVantage) position it to benefit from the expanding MA market. However, CVS faces ongoing litigation charges and regulatory risks, which tempered Q2 profitability. Overall, the MA growth reinforces the view that medical cost trends are normalizing, supporting management's raised 2025 adjusted EPS guidance.

Implication

Sustained MA enrollment and margin normalization, combined with cost savings and transparent pricing, could drive earnings recovery and multiple expansion. However, any renewed utilization spike or adverse PBM regulation would undermine the thesis.

Thesis delta

The MA growth data strengthens the case for stable Health Care Benefits margins, a key pillar of the BUY thesis. This reduces risk of a downside surprise, though litigation and PBM regulation remain critical watch items. The delta is positive but not transformative, given existing uncertainties.